22 May 2013
GENERICS, the bane of the research-based pharmaceutical industry, are a very important aspect of the health care industry to monitor, as more and more governments around the world are pushing for their greater use in order to contain health care budgets, while the launch of copy products on patent expiry - and often even before this actually occurs - can wipe billions of dollars off drugmakers’ revenues.
21 May 2013
Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in

21 May 2013
Denmark-based Novo A/S, the holding company of the Novo Group and the major shareholder in
20 May 2013
US generics major Actavis (NYSE: ACT) revealed today (May 20) that it has entered into a definitive
20 May 2013
One of the most important preconditions for Turkey to reach a reformist, sustainable economic
20 May 2013
India's National Pharmaceutical Pricing Authority (NPPA) last week announced plans that will
20 May 2013
US drugmaker Impax Laboratories (Nasdaq: IPXL) says that its generics division, Global Pharmaceuticals,
16 May 2013
US Health and Human Services (HHS) Secretary Kathleen Sebelius announced that the US Senate
01 January 2013
27 December 2012
27 December 2012
21 December 2012
20 December 2012
18 December 2012
17 December 2012
17 December 2012
16 December 2012
16 December 2012
15 December 2012